GlassScriptPhysician profile
Ashima Mittal
NPI 1760905681
$330.74
in general payments reported to CMS, 2019-2025
10 companies · $19.98 in 2025
The $19.98 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.89 · 2021: $110 · 2022: $173 · 2023: $14.16 · 2025: $19.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $19.98 · Food and Beverage: $14.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $19.98 |
| Food and Beverage | $14.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $79.78 | 2022 | |
| Novo Nordisk INC | $74.28 | 2021-2022 | |
| Dexcom, INC. | $38.04 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $36.65 | 2022-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $19.98 | 2025 | Freestyle Insulinx |
| Antares Pharma, INC. | $19.17 | 2021 | |
| Ascensia Diabetes Care US INC. | $17.71 | 2021 | |
| Clarus Therapeutics INC. | $16.27 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.97 | 2021 | |
| Lilly USA, LLC | $13.89 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashima Mittal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.